Table 1. Serology profiles of the 13 individuals who seroconverted.
1st serology test | 2nd serology test | 3rd serology test | 4th serology test | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gender | Study no. | No. of days since exposure | MBA | GAA | No. of days since exposure | MBA | GAA | No. of days since exposure | MBA | GAA | No. of days since exposure | MBA | GAA |
F | 4 | 70 | 0 | 0 | 124 | 16 | 0 | 452 | 32 | 16 | |||
F | 8 | 74 | 16 | 64 | 134 | 0 | 256 | 333 | 0 | 128 | |||
F | 9 | 69 | 0 | 0 | 131 | 0 | 256 | 413 | 0 | 32 | |||
F | 10 | 45 | 0 | 128 | 114 | 0 | 512 | ||||||
F | 11 | 63 | 0 | 0 | 161 | 0 | 256 | ||||||
F | 15 | 53 | 0 | 256 | 61 | 0 | 2048 | 268 | 0 | 256 | |||
M | 21 | 61 | 0 | 0 | 83 | 64 | 512 | 102 | 32 | 128 | 322 | 0 | 64 |
M | 25 | 50 | 0 | 128 | 73 | 0 | 256 | 267 | 0 | 512 | |||
M | 28 | 62 | 256 | 0 | 413 | 64 | 0 | ||||||
M | 30 | 71 | 0 | 256 | 106 | 0 | 512 | ||||||
M | 31 | 61 | 0 | 512 | 81 | 0 | 1024 | 426 | 0 | 256 | |||
M | 32 | 61 | 0 | 512 | 124 | 0 | 512 | 183 | 0 | 256 | 269 | 0 | 128 |
M | 36 | 74 | 256 | 1024 | 104 | 64 | 1024 | 284 | 128 | 128 |
F, Female; M, male.